A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-I, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
This is a clinical trial of rigosertib that will be administered by mouth which is investigational.
IRB Protocol #
DEREK SCHATZ at (720)848-0628 or DEREK.SCHATZ@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 48 weeks. A follow up period will consist of physician contact and clinic visit. // Eligibility criteria include but are not limited to 18 years or older with myelodysplastic syndrome (MDS).Eligibility criteria include but are not limited to 18 years or older with myelodysplastic syndrome (MDS).